{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:32:24Z","timestamp":1790551944175,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation (CHDI)","doi-asserted-by":"publisher","award":["ResearchAgreement_CHDI_Univof Maryland_Cheer_RecID_A_"],"award-info":[{"award-number":["ResearchAgreement_CHDI_Univof Maryland_Cheer_RecID_A_"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41386-018-0107-8","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T16:09:19Z","timestamp":1527869359000},"page":"2056-2063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington\u2019s disease"],"prefix":"10.1038","volume":"43","author":[{"given":"Dan P.","family":"Covey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Dantrassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-7559","authenticated-orcid":false,"given":"Joseph F.","family":"Cheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"107_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M MacDonald","year":"1993","unstructured":"MacDonald M, Ambrose C, Duyao M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"107_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington\u2019s disease. Lancet. 2007;369:218\u201328.","journal-title":"Lancet"},{"key":"107_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S. Treatment of Huntington\u2019s disease. Neurotherapeutics. 2014;11:153\u201360.","journal-title":"Neurotherapeutics"},{"key":"107_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","volume":"173","author":"EA Epping","year":"2016","unstructured":"Epping EA, Kim JI, Brashers-Krug TM, Anderson KE, McCusker E, Luther J, et al. Longitudinal psychiatric symptoms in prodromal Huntington\u2019s disease: a decade of data. Am J Psychiatry. 2016;173:184\u201392.","journal-title":"Am J Psychiatry"},{"key":"107_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington\u2019s disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"107_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1176\/jnp.2009.21.3.266","volume":"21","author":"P Naarding","year":"2009","unstructured":"Naarding P, Janzing JG, Eling P, van der Werf S, Kremer B. Apathy is not depression in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 2009;21:266\u201370.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"107_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1176\/appi.neuropsych.11030057","volume":"24","author":"JC Thompson","year":"2012","unstructured":"Thompson JC, Harris J, Sollom AC, Stopford CL, Howard E, Snowden JS, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 2012;24:53\u201360.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"107_CR8","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD, D\u2019Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 1988;85:5733\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"107_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369\u201384.","journal-title":"J Neuropathol Exp Neurol"},{"key":"107_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2017.00011","volume":"8","author":"H Wilson","year":"2017","unstructured":"Wilson H, De Micco R, Niccolini F, Politis M. Molecular imaging markers to track Huntington\u2019s disease pathology. Front Neurol. 2017;8:11.","journal-title":"Front Neurol"},{"key":"107_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/bph.13215","volume":"173","author":"C Garcia","year":"2016","unstructured":"Garcia C, Palomo-Garo C, Gomez-Galvez Y, Fernandez-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016;173:2069\u201379.","journal-title":"Br J Pharmacol"},{"key":"107_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","volume":"211","author":"C Cepeda","year":"2014","unstructured":"Cepeda C, Murphy KP, Parent M, Levine MS. The role of dopamine in Huntington\u2019s disease. Prog Brain Res. 2014;211:235\u201354.","journal-title":"Prog Brain Res"},{"key":"107_CR13","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/138161208785740108","volume":"14","author":"MR Pazos","year":"2008","unstructured":"Pazos MR, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntington\u2019s disease. Curr Pharm Des. 2008;14:2317\u201325.","journal-title":"Curr Pharm Des"},{"key":"107_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0304-3940(91)90448-3","volume":"132","author":"EK Richfield","year":"1991","unstructured":"Richfield EK, O\u2019Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington\u2019s disease. Neurosci Lett. 1991;132:121\u20136.","journal-title":"Neurosci Lett"},{"key":"107_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience. 2000;97:505\u201319.","journal-title":"Neuroscience"},{"key":"107_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.410220318","volume":"22","author":"SJ Kish","year":"1987","unstructured":"Kish SJ, Shannak K, Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington\u2019s disease striatum. Ann Neurol. 1987;22:386\u20139.","journal-title":"Ann Neurol"},{"key":"107_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","volume":"163","author":"MJ Dowie","year":"2009","unstructured":"Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington\u2019s disease. Neuroscience. 2009;163:456\u201365.","journal-title":"Neuroscience"},{"key":"107_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.neuron.2011.11.018","volume":"73","author":"EB Oleson","year":"2012","unstructured":"Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron. 2012;73:360\u201373.","journal-title":"Neuron"},{"key":"107_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","volume":"124","author":"DP Covey","year":"2017","unstructured":"Covey DP, Mateo Y, Sulzer D, Cheer JF, Lovinger DM. Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology. 2017;124:52\u201361.","journal-title":"Neuropharmacology"},{"key":"107_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/ejn.13248","volume":"43","author":"DP Covey","year":"2016","unstructured":"Covey DP, Bunner KD, Schuweiler DR, Cheer JF, Garris PA. Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids. Eur J Neurosci. 2016;43:1661\u201373.","journal-title":"Eur J Neurosci"},{"key":"107_CR21","doi-asserted-by":"publisher","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","volume":"7","author":"LB Menalled","year":"2012","unstructured":"Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175. PLoS One. 2012;7:e49838.","journal-title":"PLoS One"},{"key":"107_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nmeth.1412","volume":"7","author":"JJ Clark","year":"2010","unstructured":"Clark JJ, Sandberg SG, Wanat MJ, Gan JO, Horne EA, Hart AS, et al. Chronic microsensors for longitudinal, subsecond dopamine detection in behaving animals. Nat Methods. 2010;7:126\u20139.","journal-title":"Nat Methods"},{"key":"107_CR23","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1073\/pnas.0504657102","volume":"102","author":"ML Heien","year":"2005","unstructured":"Heien ML, Khan AS, Ariansesn JL, Cheer JC, Phillips PE, Wassum KM, et al. Real-time measurement of dopamine fluctuations after cocaine in the brain of behaving rats. Proc Natl Acad Sci USA. 2005;102:10023\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"107_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1021\/cn200035u","volume":"2","author":"RB Keithley","year":"2011","unstructured":"Keithley RB, Wightman RM. Assessing principal component regression prediction of neurochemicals detected with fast-scan cyclic voltammetry. ACS Chem Neurosci. 2011;2:514\u201325.","journal-title":"ACS Chem Neurosci"},{"key":"107_CR25","doi-asserted-by":"publisher","first-page":"11568","DOI":"10.1021\/ac402884n","volume":"85","author":"JG Roberts","year":"2013","unstructured":"Roberts JG, Toups JV, Eyualem E, McCarty GS, Sombers LA. In situ electrode calibration strategy for voltammetric measurements in vivo. Anal Chem. 2013;85:11568\u201375.","journal-title":"Anal Chem"},{"key":"107_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuint.2006.06.004","volume":"49","author":"CE John","year":"2006","unstructured":"John CE, Jones SR. Exocytotic release of dopamine in ventral tegmental area slices from C57BL\/6 and dopamine transporter knockout mice. Neurochem Int. 2006;49:737\u201345.","journal-title":"Neurochem Int"},{"key":"107_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jneumeth.2011.03.001","volume":"202","author":"JT Yorgason","year":"2011","unstructured":"Yorgason JT, Espana RA, Jones SR. Demon voltammetry and analysis software: analysis of cocaine-induced alteration in dopamine signaling using multiple kinetic measures. J Neurosci Methods. 2011;202:158\u201364.","journal-title":"J Neurosci Methods"},{"key":"107_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1126\/science.134.3483.943","volume":"134","author":"W Hodos","year":"1961","unstructured":"Hodos W. Progressive ratio as a measure of reward strength. Science. 1961;134:943\u20134.","journal-title":"Science"},{"key":"107_CR29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.neuron.2017.11.012","volume":"96","author":"Y Mateo","year":"2017","unstructured":"Mateo Y, Johnson KA, Covey DP, Atwod BK, Wang HL, Zhang S, et al. Endocannabinoids on cortical terminals orchestrate local modulation of dopamine release in the nucleus accumbens. Neuron. 2017;96:1112\u201326.","journal-title":"Neuron"},{"key":"107_CR30","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/npp.2013.340","volume":"39","author":"EB Oleson","year":"2014","unstructured":"Oleson EB, Cachope R, Fitoussi A, Tsutsui K, Wu S, Gallegos JA, et al. Cannabinoid receptor activation shifts temporally engendered patterns of dopamine release. Neuropsychopharmacology. 2014;39:1441\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"107_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nchembio.129","volume":"5","author":"JZ Long","year":"2009","unstructured":"Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009;5:37\u201344.","journal-title":"Nat Chem Biol"},{"key":"107_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/7854_2015_383","volume":"27","author":"JD Salamone","year":"2016","unstructured":"Salamone JD, Pardo M, Yohn SE, Lopez-Cruz L, SanMiguel N, Correa M. Mesolimbic dopamine and the regulation of motivated behavior. Curr Top Behav Neurosci. 2016;27:231\u201357.","journal-title":"Curr Top Behav Neurosci"},{"key":"107_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1471-4159.2006.03762.x","volume":"97","author":"MA Johnson","year":"2006","unstructured":"Johnson MA, Rajan V, Miller CE, Wightman RM. Dopamine release is severely compromised in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem. 2006;97:737\u201346.","journal-title":"J Neurochem"},{"key":"107_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/BF02245133","volume":"107","author":"JD Salamone","year":"1992","unstructured":"Salamone JD. Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes. Psychopharmacology (Berl). 1992;107:160\u201374.","journal-title":"Psychopharmacology (Berl)"},{"key":"107_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cercor\/bhj043","volume":"16","author":"R Levy","year":"2006","unstructured":"Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16:916\u201328.","journal-title":"Cereb Cortex"},{"key":"107_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0301-0082(80)90018-0","volume":"14","author":"GJ Mogenson","year":"1980","unstructured":"Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol. 1980;14:69\u201397.","journal-title":"Prog Neurobiol"},{"key":"107_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1196\/annals.1390.018","volume":"1104","author":"Y Niv","year":"2007","unstructured":"Niv Y. Cost, benefit, tonic, phasic: what do response rates tell us about dopamine and motivation? Ann NY Acad Sci. 2007;1104:257\u2013376.","journal-title":"Ann NY Acad Sci"},{"key":"107_CR38","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1523\/JNEUROSCI.1279-15.2016","volume":"36","author":"D Ko","year":"2016","unstructured":"Ko D, Wanat MJ. Phasic dopamine transmission reflects initiation vigor and exerted effort in an action- and region-specific manner. J Neruosci. 2016;36:2202\u201311.","journal-title":"J Neruosci"},{"key":"107_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev.pa.20.040180.002533","volume":"20","author":"ED Bird","year":"1980","unstructured":"Bird ED. Chemical pathology of Huntington\u2019s disease. Annu Rev Pharmacol Toxicol. 1980;20:533\u201351.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"107_CR40","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(70)90367-3","volume":"2","author":"HC Klawans","year":"1970","unstructured":"Klawans HC, Paulson GW, Barbeau A. Predictive test for Huntington\u2019s chorea. Lancet. 1970;2:1185\u20136.","journal-title":"Lancet"},{"issue":"Pt 12","key":"107_CR41","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","volume":"120","author":"L Backman","year":"1997","unstructured":"Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington\u2019s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(Pt 12):2207\u201317.","journal-title":"Brain"},{"key":"107_CR42","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1523\/JNEUROSCI.0135-16.2016","volume":"36","author":"DP Covey","year":"2016","unstructured":"Covey DP, Dantrassy HM, Zlebnik NE, Gildish I, Cheer JF. Compromised dopaminergic encoding of reward accompanying suppressed willingness to overcome high effort costs is a prominent prodromal characteristic of the Q175 mouse model of Huntington\u2019s disease. J Neurosci. 2016;36:4993\u20135002.","journal-title":"J Neurosci"},{"key":"107_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Bl\u00e0zquez","year":"2011","unstructured":"Bl\u00e0zquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain. 2011;134:119\u201336.","journal-title":"Brain"},{"key":"107_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol. 2014;29:1\u20138.","journal-title":"Curr Opin Neurobiol"},{"key":"107_CR45","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.celrep.2015.08.041","volume":"12","author":"H Wang","year":"2015","unstructured":"Wang H, Treadway T, Covey DP, Cheer JF, Lupica CR. Cocaine-induced endocannabinoid mobilization in the ventral tegmental area. Cell Rep. 2015;12:1997\u20132008.","journal-title":"Cell Rep"},{"key":"107_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neuint.2007.07.014","volume":"52","author":"Z Sidlo","year":"2008","unstructured":"Sidlo Z, Reggio PH, Rice ME. Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels. Neurochem Int. 2008;52:80\u20138.","journal-title":"Neurochem Int"},{"key":"107_CR47","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/j.1755-5949.2010.00144.x","volume":"16","author":"J Fernandez-Ruiz","year":"2010","unstructured":"Fernandez-Ruiz J, Hernandez M, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:e72\u201391.","journal-title":"CNS Neurosci Ther"},{"key":"107_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/syn.10054","volume":"44","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, P\u00e8rez-Rosado A, Manzanares J, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington\u2019s disease. Synapse. 2002;44:23\u201335.","journal-title":"Synapse"},{"key":"107_CR49","doi-asserted-by":"publisher","first-page":"E684","DOI":"10.3390\/ijms18040684","volume":"18","author":"S Valdeolivas","year":"2017","unstructured":"Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernandez-Ruiz J. Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington\u2019s disease. Int J Mol Sci. 2017;18:E684.","journal-title":"Int J Mol Sci"},{"key":"107_CR50","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JL L\u00f2pez-Send\u00f2n Moreno","year":"2016","unstructured":"L\u00f2pez-Send\u00f2n Moreno JL, Garcia Caldentey J, Trigo Cubillo P, Ruiz-Romero C, Garcia Ribas G, Alonso Arias MA, et al. A double-blind, randomized, cross-over, placebo- controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol. 2016;263:1390\u20131400.","journal-title":"J Neurol"},{"key":"107_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pharmthera.2017.02.033","volume":"175","author":"GF Grabner","year":"2017","unstructured":"Grabner GF, Zimmermann R, Schicho R, Taschler U. Monoglyceride lipase as a drug target: at the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther. 2017;175:35\u201346.","journal-title":"Pharmacol Ther"},{"key":"107_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.lfs.2012.10.025","volume":"92","author":"MM Mulvihill","year":"2013","unstructured":"Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013;92:492\u20137.","journal-title":"Life Sci"},{"key":"107_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drugalcdep.2014.11.015","volume":"146","author":"TF Gamage","year":"2015","unstructured":"Gamage TF, Ignatowska-Jankowska BM, Muldoon PP, Cravatt BF, Damaj MI, Lichtman AH. Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. Drug Alcohol Depend. 2015;146:7\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"107_CR54","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bph.12948","volume":"172","author":"PP Muldoon","year":"2015","unstructured":"Muldoon PP, Chen J, Harenza JL, Abdullah RA, Sim-Selley LJ, Cravatt BF, Miles MF, Chen X, Lichtman AH, Damaj MI. Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Brit J Pharmacol. 2015;172:869\u201382.","journal-title":"Brit J Pharmacol"},{"key":"107_CR55","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/13543776.2018.1389899","volume":"27","author":"C Granchi","year":"2017","unstructured":"Granchi C, Caligiuri I, Minutolo F, Rizzolio F, Tuccinardi T. A patent review of monoacylglycerol lipase (MAGL) inhibitors (2013-7). Expert Opin Ther Pat. 2017;27:1341\u201351.","journal-title":"Expert Opin Ther Pat"},{"key":"107_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00004714-199010000-00007","volume":"10","author":"R Hoehn-Saric","year":"1990","unstructured":"Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990;10:343\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"107_CR57","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/npp.2015.188","volume":"41","author":"SE Yohn","year":"2016","unstructured":"Yohn SE, Collins SL, Contreras-Mora HM, Errante EL, Rowland MA, Correa M, et al. Not all antidepressants are created equal: differential effects of monoamine uptake inhibitors on effort-related choice behavior. Neuropsychopharmacology. 2016;41:686\u201394.","journal-title":"Neuropsychopharmacology"},{"key":"107_CR58","first-page":"545","volume":"3","author":"D Paleacu","year":"2007","unstructured":"Paleacu D. Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat. 2007;3:545\u201351.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"107_CR59","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/mds.26014","volume":"29","author":"A Killoran","year":"2014","unstructured":"Killoran A, Biglan KM. Current therapeutic options for Huntington\u2019s disease: good clinical practice versus evidence-based approaches? Mov Disord. 2014;29:1404\u201313.","journal-title":"Mov Disord"},{"key":"107_CR60","doi-asserted-by":"publisher","first-page":"e99320","DOI":"10.1371\/journal.pone.0099320","volume":"9","author":"PA Randall","year":"2014","unstructured":"Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, et al. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio\/chow feeding choice task: reversal with antidepressant drugs. PLoS One. 2014;9:e99320.","journal-title":"PLoS One"},{"key":"107_CR61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00213-014-3766-0","volume":"232","author":"SE Yohn","year":"2015","unstructured":"Yohn SE, Thompson C, Randall PA, Lee CA, M\u00fcller CE, Bagi Y, et al. The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl). 2015;232:1313\u201323.","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0107-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:22Z","timestamp":1684616602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0107-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0107-8","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"assertion":[{"value":"13 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}